About
Approach
Investment Model
Investment Scope
Our approach
Team
Managing Partner
Partners
Venture Partners
Our team
Portfolio
News
Connect
Pages
Pages
Home
About
Blog
Blog Post
Contact
Portfolio
Investors
Investor Single
Shop
Shop Single
Utility Pages
Start Here
Style Guide
404 Not Found
Password Protected
Licenses
Changelog
Browse More Templates
Chime Biologics Announces Strategic Collaboration with Beijing Libang Pharmaceutical on Global Blinatumomab Biosimilar Program
Article Date
December 10, 2025
This article is featured on another website.
Go to article
Related posts
Browse all articles
February 10, 2026
Kainova Therapeutics secures $CAD 32 million to accelerate the development of its immuno-oncology and inflammation portfolio.
February 10, 2026
Kainova Therapeutics secures $CAD 32 million to accelerate the development of its immuno-oncology and inflammation portfolio.
January 15, 2026
Q&A with Sean A. MacDonald, Chief Executive Officer at Kainova Therapeutics
January 15, 2026
Q&A with Sean A. MacDonald, Chief Executive Officer at Kainova Therapeutics
